This presentation will discuss gene-drug pairs relevant in cardiology, describe how PGx variation affects the pharmacokinetics and pharmacodynamics of cardiovascular agents, and review seminal clinical trial data impacting PGx implementation in cardiology. Faculty will review the availability of evidence-based PGx guidelines relevant to the prescribing of antiplatelets, statins, and warfarin and explain how patient factors (ancestry, treatment intensity, concomitant therapy, etc) are integrated into PGx algorithms. Finally, a review of specific challenges to PGx implementation in cardiology, focusing on clopidogrel will be covered.

Learning Objectives

At the conclusion of this activity, participants should be able to:

• Describe how PGx variation affects the pharmacokinetics and pharmacodynamics of cardiovascular agents
• Recognize the availability of evidence-based PGx guidelines relevant to the prescribing of antiplatelets, statins, and warfarin
• Give examples of clinical situations when PGx is likely to be useful in cardiology